Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma is currently developing IV/IM Meloxicam, a proprietary, Phase III-ready, rapid-onset, long-acting preferential COX-2 inhibitor, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine in Phase II, both for the treatment of acute post operative pain. As Recro Pharma's product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. Recro Pharma owns and operates an 97,000 square foot, DEA-licensed facility that manufactures five commercial products that are commercialized by partners and receives royalties associated with the sales of these products. Source
No articles found.
Headquartered in Bedford, Massachusetts, Anika Therapeutics, Inc. develops, manufa...
Headquartered in Bedford, Massachusetts, Anika ...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...
Arcturus Therapeutics is developing portfolio o...
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...
Founded in 2006 and headquartered in San Diego,...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
We at Auris Medical are dedicated to developing novel pharmaceutical products for ...
We at Auris Medical are dedicated to developing...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Join the National Investor Network and get the latest information with your interests in mind.